Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Carrygenes Bioengineering LLC has 2 pending office actions currently active in its portfolio. These matters are assigned to 2 distinct examiners, ensuring that each action receives a separate review. The portfolio currently shows 0 distinct art units, which indicates that the pending applications are grouped within a single technical classification or are at a similar stage of the process.
JUEDES, AMY E is the busiest examiner for the company, handling 1 of the pending office actions. With 2 pending office actions total, the prosecution strategy is divided between the 2 distinct examiners. The 0 art units associated with these filings suggest a concentrated technical focus. Practitioners should focus on the 1 pending action under JUEDES, AMY E while maintaining a consistent strategy for the other pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUMPHRIES, NICHOLAS ADAM | 1 | 36.1% | +75.9% |
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 19d overdue |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 19d overdue |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | — |
| 18685914 | Synthetic Chromosome Encoding Two Or More Chimeric Antigen Receptors Binding To Tumor Associated Antigens | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | HUMPHRIES, NICHOLAS ADAM | — | §102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18685914 | Synthetic Chromosome Encoding Two Or More Chimeric Antigen Receptors Binding To Tumor Associated Antigens | JUEDES, AMY E | — | §103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 17582609 | Methods of Cell Renewal | REGLAS, GILLIAN CHELSEA | 1632 | §102§103§112 | Final Rejection | 19d overdue | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial